Mycobacterium kansasii cutaneous infection in a patient with sarcoidosis treated with anti-TNF agents.
We describe a Mycobacterium kansasii cutaneous infection that was diagnosed in a 52-year-old female patient with sarcoidosis receiving anti-TNF agents. The diagnosis was based on the positive culture of the foot ulcerative tissue. The isolation and identification of bacterium was based on phenotypic and molecular methods. Therapy and follow-up of the patient is discussed.
I
I
Spiliopoulou
A
A
Foka
A
A
Bounas
M N
MN
Marangos
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D019909:Mycobacterium kansasii; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012507:Sarcoidosis / Q000150:complications / Q000188:drug therapy*; D017192:Skin Diseases, Bacterial / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept
Anti-TNF agents; Mycobacterium kansasii,